Literature DB >> 27790442

Clinicopathological Study of Triple Negative Breast Cancers.

Gunadala Ishitha1, Marie Therese Manipadam2, Selvamani Backianathan3, Raju Titus Chacko4, Deepak Thomas Abraham5, Paul Mazhuvanchary Jacob6.   

Abstract

INTRODUCTION: Triple Negative Breast Cancers (TNBC) are a subset of breast cancers which are composed of different molecular subtypes. The most common is the basal like subtype, which has an adverse prognosis and limited treatment options. AIM: This study was undertaken to assess the clinico-pathologic and immunohistochemical subtypes of triple negative breast cancers and assess how each of these subtypes correlate with clinical behaviour and survival outcomes.
MATERIALS AND METHODS: Fifty-three (22.2%) of 238 cases of primary invasive breast carcinomas diagnosed from January 2010 to June 2011 were found to be negative for immunohistochemical markers- ER, PR and HER2. These fifty three cases were included in the study and were classified into four histological subtypes proposed by Ishikawa et al. Basal markers- CK5/6, EGFR and CK14 were done on these cases and they were further classified immunohistochemically into basal and non basal subtypes. The morphological features, disease free survival and overall survival were evaluated for both basal and non basal subtypes.
RESULTS: Majority (96%) of TNBC cases were classified according to WHO as invasive ductal carcinoma (NOS). Type C Ishikawa histological subtype was found to be the commonest subtype in both basal and non-basal TNBC. Of 53 TNBC cases, basal immunohistochemical markers were performed on 47 cases only because of paucity of tissue. Of these 47 cases, thirty-five (74.4%) were found to be of basal like subtype and all these cases were picked up by a combination of CK5/6 and EGFR.
CONCLUSION: High grade morphological features, hormonal markers with additional use of basal markers can help identify the basal like subtype of TNBC, thereby predicting breast cancer survival. The combination of CK5/6 and EGFR identified all cases of basal subtype. EGFR in addition also has potential therapeutic implications. The morphological features and survival outcomes were not significantly different between basal and non-basal phenotypes.

Entities:  

Keywords:  Basal like; Estrogen; Non basal; Progesterone

Year:  2016        PMID: 27790442      PMCID: PMC5071942          DOI: 10.7860/JCDR/2016/20475.8539

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  38 in total

1.  A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.

Authors:  Yahong Wang; Quangui Yin; Qi Yu; Jing Zhang; Ziyu Liu; Shuling Wang; Shuhua Lv; Yun Niu
Journal:  Breast Cancer Res Treat       Date:  2011-08-12       Impact factor: 4.872

Review 2.  Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists.

Authors:  Sunil Badve; David J Dabbs; Stuart J Schnitt; Frederick L Baehner; Thomas Decker; Vincenzo Eusebi; Stephen B Fox; Shu Ichihara; Jocelyne Jacquemier; Sunil R Lakhani; José Palacios; Emad A Rakha; Andrea L Richardson; Fernando C Schmitt; Puay-Hoon Tan; Gary M Tse; Britta Weigelt; Ian O Ellis; Jorge S Reis-Filho
Journal:  Mod Pathol       Date:  2010-11-12       Impact factor: 7.842

3.  Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India.

Authors:  Moses Ambroise; Mitra Ghosh; V S Mallikarjuna; Ann Kurian
Journal:  Asian Pac J Cancer Prev       Date:  2011

Review 4.  Triple-negative breast cancer: epidemiological considerations and recommendations.

Authors:  P Boyle
Journal:  Ann Oncol       Date:  2012-08       Impact factor: 32.976

5.  Triple negative breast cancer: outcome correlation with immunohistochemical detection of basal markers.

Authors:  Aye Aye Thike; Jabed Iqbal; Poh Yian Cheok; Angela Phek Yoon Chong; Gary Man-Kit Tse; Benita Tan; Patrick Tan; Nan Soon Wong; Puay Hoon Tan
Journal:  Am J Surg Pathol       Date:  2010-07       Impact factor: 6.394

6.  Immunohistochemical characterization of molecular subtypes of invasive breast cancer: a study from North India.

Authors:  Sangeeta Verma; Amanjit Bal; Kusum Joshi; Sunil Arora; Gurpreet Singh
Journal:  APMIS       Date:  2012-07-26       Impact factor: 3.205

7.  Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.

Authors:  Torsten O Nielsen; Forrest D Hsu; Kristin Jensen; Maggie Cheang; Gamze Karaca; Zhiyuan Hu; Tina Hernandez-Boussard; Chad Livasy; Dave Cowan; Lynn Dressler; Lars A Akslen; Joseph Ragaz; Allen M Gown; C Blake Gilks; Matt van de Rijn; Charles M Perou
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

Review 8.  Understanding and treating triple-negative breast cancer.

Authors:  Carey Anders; Lisa A Carey
Journal:  Oncology (Williston Park)       Date:  2008-10       Impact factor: 2.990

9.  Triple negative breast cancer - our experience and review.

Authors:  S Krishnamurthy; R Poornima; Vasu Reddy Challa; Y G Basavana Goud
Journal:  Indian J Surg Oncol       Date:  2012-02-25

10.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.

Authors:  C W Elston; I O Ellis
Journal:  Histopathology       Date:  1991-11       Impact factor: 5.087

View more
  2 in total

1.  Meta-Analysis of Prevalence of Triple-Negative Breast Cancer and Its Clinical Features at Incidence in Indian Patients With Breast Cancer.

Authors:  Apurv Kulkarni; Devaki A Kelkar; Nidhi Parikh; Lingadahalli S Shashidhara; Chaitanyanand B Koppiker; Madhura Kulkarni
Journal:  JCO Glob Oncol       Date:  2020-07

2.  Subtyping Of Triple Negative Breast Carcinoma On The Basis Of RTK Expression.

Authors:  Harald Hessel; Manuela Poignée-Heger; Sabine Lohmann; Bianca Hirscher; Andrea Herold; Gerald Assmann; Jan Budczies; Karl Sotlar; Thomas Kirchner
Journal:  J Cancer       Date:  2018-06-23       Impact factor: 4.207

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.